Ruxolitinib cream study for hidradenitis suppurativa
Treatments studied
Part of Infections, Skin clinical trials.
This study tests a cream called ruxolitinib for people with hidradenitis suppurativa (HS). The goal is to see how much of the cream is absorbed when it's applied to a large area of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HS for at least 6 months.
- You have at least 4 abscesses or inflamed lumps (nodules) affecting at least 3 different body areas.
- The treatment area on your skin is larger than 20% of your total body surface.
- You agree not to use other topical or oral antibiotics for HS during the treatment period.
- You are willing to avoid pregnancy or fathering children as described in the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new daily pill called zasocitinib for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. It aims to reduce painful lumps and abscesses.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
This study tests a new oral medication, remibrutinib, in adults with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful lumps and tunnels. The goal is to see how the drug affects the skin tissue and to gather information for future treatments.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tests the long-term safety and effectiveness of remibrutinib for people with moderate to severe hidradenitis suppurativa (HS) who have already completed a 68-week treatment period in a related study.
This trial tests a cream called ruxolitinib for adults with vitiligo on the face and neck that has not responded well to another cream (tacrolimus). The goal is to see if this cream can help bring back skin color.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.